Absci
runs Origin-1, a generative AI platform for de novo antibody design against novel epitopes, and collaborated with Twist Bioscience to combine generative-AI drug creation with DNA synthesis.
- Country
- United States
- Ticker
- NASDAQ:ABSI
US
Coverage
| EU | US | |
|---|---|---|
| digital-it | ✓ | ✓ |
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI strain-design & engineering platforms | digital-it | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.